These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 2968875)

  • 1. Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus.
    Sjövall J; Karlsson A; Ogenstad S; Sandström E; Saarimäki M
    Clin Pharmacol Ther; 1988 Jul; 44(1):65-73. PubMed ID: 2968875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection.
    Sjövall J; Bergdahl S; Movin G; Ogenstad S; Saarimäki M
    Antimicrob Agents Chemother; 1989 Jul; 33(7):1023-31. PubMed ID: 2528939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis.
    Aweeka F; Gambertoglio J; Mills J; Jacobson MA
    Antimicrob Agents Chemother; 1989 May; 33(5):742-5. PubMed ID: 2546491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS.
    Jacobson MA; Crowe S; Levy J; Aweeka F; Gambertoglio J; McManus N; Mills J
    J Infect Dis; 1988 Oct; 158(4):862-5. PubMed ID: 2844921
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetics of potential anti-AIDS agents thiofoscarnet and foscarnet in the cat.
    Straw JA; Loo TL; de Vera CC; Nelson PD; Tompkins WA; Bai SA
    J Acquir Immune Defic Syndr (1988); 1992; 5(9):936-42. PubMed ID: 1387417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of foscarnet (phosphonoformate) on human immunodeficiency virus isolation, T-cell subsets and lymphocyte function in AIDS patients.
    Gaub J; Pedersen C; Poulsen AG; Mathiesen LR; Ulrich K; Lindhardt BO; Faber V; Gerstoft J; Hofmann B; Lernestedt JO
    AIDS; 1987 May; 1(1):27-33. PubMed ID: 2962590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Foscarnet.
    Med Lett Drugs Ther; 1992 Jan; 34(861):3-4. PubMed ID: 1309469
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients.
    Reusser P; Gambertoglio JG; Lilleby K; Meyers JD
    J Infect Dis; 1992 Sep; 166(3):473-9. PubMed ID: 1323614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful foscarnet therapy for cytomegalovirus retinitis in an AIDS patient undergoing hemodialysis: rationale for empiric dosing and plasma level monitoring.
    MacGregor RR; Graziani AL; Weiss R; Grunwald JE; Gambertoglio JG
    J Infect Dis; 1991 Oct; 164(4):785-7. PubMed ID: 1654363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis.
    Chrisp P; Clissold SP
    Drugs; 1991 Jan; 41(1):104-29. PubMed ID: 1706982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism.
    Jacobson MA; Gambertoglio JG; Aweeka FT; Causey DM; Portale AA
    J Clin Endocrinol Metab; 1991 May; 72(5):1130-5. PubMed ID: 1827127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacology: foscarnet.
    Lietman PS
    Am J Med; 1992 Feb; 92(2A):8S-11S. PubMed ID: 1371039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of zidovudine administered intravenously and orally in children with human immunodeficiency virus infection.
    Balis FM; Pizzo PA; Eddy J; Wilfert C; McKinney R; Scott G; Murphy RF; Jarosinski PF; Falloon J; Poplack DG
    J Pediatr; 1989 May; 114(5):880-4. PubMed ID: 2715903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and absolute bioavailability of oral foscarnet in human immunodeficiency virus-seropositive patients.
    Noormohamed FH; Youle MS; Higgs CJ; Martin-Munley S; Gazzard BG; Lant AF
    Antimicrob Agents Chemother; 1998 Feb; 42(2):293-7. PubMed ID: 9527775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group.
    Safrin S; Crumpacker C; Chatis P; Davis R; Hafner R; Rush J; Kessler HA; Landry B; Mills J
    N Engl J Med; 1991 Aug; 325(8):551-5. PubMed ID: 1649971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypocalcemia induced by foscarnet (Foscavir) infusion in dogs.
    Ryrfeldt A; Nordgren T; Lundström J
    Fundam Appl Toxicol; 1992 Jan; 18(1):126-30. PubMed ID: 1534776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal excretion and pharmacokinetics of foscarnet in HIV sero-positive patients: effect of probenecid pretreatment.
    Noormohamed FH; Youle MS; Higgs CJ; Gazzard BG; Lant AF
    Br J Clin Pharmacol; 1997 Jan; 43(1):112-5. PubMed ID: 9056062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients.
    Ringdén O; Lönnqvist B; Paulin T; Ahlmén J; Klintmalm G; Wahren B; Lernestedt JO
    J Antimicrob Chemother; 1986 Mar; 17(3):373-87. PubMed ID: 3009383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experiences with phosphonoformate (foscarnet) treatment of viral diseases following renal transplantation.
    Ahlmén J; Wijnween AC; Brynger H; Lycke E
    Scand J Urol Nephrol Suppl; 1985; 92():41-4. PubMed ID: 3008316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo additive antiretroviral effect of combined zidovudine and foscarnet therapy for human immunodeficiency virus infection (ACTG Protocol 053).
    Jacobsen MA; van der Horst C; Causey DM; Dehlinger M; Hafner R; Mills J
    J Infect Dis; 1991 Jun; 163(6):1219-22. PubMed ID: 1828075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.